Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...

XOMA Royalty recorded total income and revenues of $7.2 million for the third quarter of 2024, which included $6.5 million in estimated income associated with two commercial products in our portfolio.

About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a ...

“Our third quarter and recent period have been marked by outstanding progress in advancing our pipeline of CRISPR-based gene editing therapies,” said Intellia President and Chief Executive Officer ...

CAMBRIDGE, Mass. & MONTREAL, November 07, 2024 -- ( BUSINESS WIRE )--Repare Therapeutics Inc. ("Repare" or the "Company") ...

Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP –– Commenced startup for a Phase 2 clinical trial in ...

Key updated preliminary results from the Phase 3 ENLIGHTED study of Padeliporfin VTP: Padeliporfin VTP was well-tolerated with a safety profile consistent with the previous data obtained from the ...

Quarter Results07.11.2024 / 12:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Immunic, Inc. Reports Third Quarter 2024 Financial Resultsand Provides Corporate Update– ...

Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...